These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36031403)

  • 1. Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials.
    Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Hill C; Gelone SP; Mariano D; Baba T; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW
    Clin Infect Dis; 2023 Feb; 76(3):e1157-e1165. PubMed ID: 36031403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection.
    Singh KP; Li G; Mitrani-Gold FS; Kurtinecz M; Wetherington J; Tomayko JF; Mundy LM
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5284-90. PubMed ID: 23939900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs.
    Kinamon T; Gopinath R; Waack U; Needles M; Rubin D; Collyar D; Doernberg SB; Evans S; Hamasaki T; Holland TL; Howard-Anderson J; Chambers H; Fowler VG; Nambiar S; Kim P; Boucher HW
    Clin Infect Dis; 2023 Aug; 77(4):649-656. PubMed ID: 37073571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
    Popejoy MW; Long J; Huntington JA
    BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Leister-Tebbe H; Hill C; Geres H; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW;
    Clin Infect Dis; 2024 Feb; 78(2):259-268. PubMed ID: 37740559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
    Huntington JA; Sakoulas G; Umeh O; Cloutier DJ; Steenbergen JN; Bliss C; Goldstein EJ
    J Antimicrob Chemother; 2016 Jul; 71(7):2014-21. PubMed ID: 26994090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.
    Doernberg SB; Tran TTT; Tong SYC; Paul M; Yahav D; Davis JS; Leibovici L; Boucher HW; Corey GR; Cosgrove SE; Chambers HF; Fowler VG; Evans SR; Holland TL;
    Clin Infect Dis; 2019 May; 68(10):1691-1698. PubMed ID: 30321315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation.
    Portsmouth S; Echols R; Toyoizumi K; Tillotson G; Nagata TD
    Ther Adv Infect Dis; 2021; 8():20499361211058257. PubMed ID: 34868583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.
    Naber KG; Llorens L; Kaniga K; Kotey P; Hedrich D; Redman R
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3782-92. PubMed ID: 19581455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
    Redman R; Damiao R; Kotey P; Kaniga K; Davies T; Naber KG
    J Chemother; 2010 Dec; 22(6):384-91. PubMed ID: 21303745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
    Lee YR; Yeo S
    Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of a Potential DOOR Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs.
    Kinamon T; Waack U; Needles M; Rubin D; Collyar D; Doernberg SB; Evans SR; Hamasaki T; Holland TL; Howard-Anderson J; Chambers H; Fowler VG; Nambiar S; Kim P; Boucher HW; Gopinath R
    Clin Infect Dis; 2024 Mar; ():. PubMed ID: 38527855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.
    Evans SR; Knutsson M; Amarenco P; Albers GW; Bath PM; Denison H; Ladenvall P; Jonasson J; Easton JD; Minematsu K; Molina CA; Wang Y; Wong KL; Johnston SC
    Clin Trials; 2020 Dec; 17(6):617-626. PubMed ID: 32666831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.
    Kaye KS; Rice LB; Dane AL; Stus V; Sagan O; Fedosiuk E; Das AF; Skarinsky D; Eckburg PB; Ellis-Grosse EJ
    Clin Infect Dis; 2019 Nov; 69(12):2045-2056. PubMed ID: 30861061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection: A systematic review and network meta-analysis.
    Tan X; Pan Q; Mo C; Li X; Liang X; Li Y; Lan Y; Chen L
    Medicine (Baltimore); 2020 Jan; 99(2):e18769. PubMed ID: 31914101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
    Kullar R; Wagenlehner FM; Popejoy MW; Long J; Yu B; Goldstein EJ
    J Antimicrob Chemother; 2017 Mar; 72(3):900-905. PubMed ID: 27999024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.
    Hung KC; Tsai WW; Hsu CW; Lai CC; Tang HJ; Chen IW
    Int J Antimicrob Agents; 2023 Jul; 62(1):106830. PubMed ID: 37100354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.
    Wagenlehner FM; Sobel JD; Newell P; Armstrong J; Huang X; Stone GG; Yates K; Gasink LB
    Clin Infect Dis; 2016 Sep; 63(6):754-762. PubMed ID: 27313268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.